Eli Lilly 2007 Annual Report Download - page 78

Download and view the complete annual report

Please find page 78 of the 2007 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 132

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132

PROXY STATEMENT
7676
Directors’ Outstanding Stock Options
Name Grant Date Expiration Date Exercise Price
Outstanding Stock Options
(Exercisable)
Sir Winfried Bischoff 2/20/2001
2/19/2002
2/18/2003
2/17/2004
2/18/2011
2/17/2012
2/18/2013
2/17/2014
$73.98
$75.92
$57.85
$73.11
2,800
2,800
2,800
2,800
Mr. Cook — — — 0
Mr. Eskew — — — 0
Dr. Feldstein 2/19/2002
2/18/2003
2/17/2004
2/17/2012
2/18/2013
2/17/2014
$75.92
$57.85
$73.11
2,800
2,800
2,800
Mr. Fisher 2/20/2001
2/19/2002
2/18/2003
2/17/2004
2/18/2011
2/17/2012
2/18/2013
2/17/2014
$73.98
$75.92
$57.85
$73.11
2,800
2,800
2,800
2,800
Mr. Fyrwald — — — 0
Dr. Gilman
4/20/2000
2/20/2001
2/19/2002
2/18/2003
2/17/2004
4/19/2010
2/18/2011
2/17/2012
2/18/2013
2/17/2014
$75.94
$73.98
$75.92
$57.85
$73.11
2,800
2,800
2,800
2,800
2,800
Ms. Horn
4/20/2000
2/20/2001
2/19/2002
2/18/2003
2/17/2004
4/19/2010
2/18/2011
2/17/2012
2/18/2013
2/17/2014
$75.94
$73.98
$75.92
$57.85
$73.11
2,800
2,800
2,800
2,800
2,800
Ms. Marram 2/18/2003
2/17/2004 2/18/2013
2/17/2014 $57.85
$73.11 2,800
2,800
Dr. Prendergast
4/20/2000
2/20/2001
2/19/2002
2/18/2003
2/17/2004
4/19/2010
2/18/2011
2/17/2012
2/18/2013
2/17/2014
$75.94
$73.98
$75.92
$57.85
$73.11
2,800
2,800
2,800
2,800
2,800
Ms. Seifert
4/20/2000
2/20/2001
2/19/2002
2/18/2003
2/17/2004
4/19/2010
2/18/2011
2/17/2012
2/18/2013
2/17/2014
$75.94
$73.98
$75.92
$57.85
$73.11
2,800
2,800
2,800
2,800
2,800
Cash Compensation
The company provides directors the following cash compensation:
• retainer of $80,000 per year (payable monthly)
• $1,000 for each committee meeting attended
• $2,000 to the committee chairpersons for each committee meeting conducted as compensation for the
chairperson’s preparation time
• retainer of $20,000 per year to the presiding director
• reimbursement for customary and usual travel expenses.
Stock Compensation
Stock compensation for directors consists of:
• shares of Lilly stock equaling $145,000, deposited annually in a deferred share account in the Lilly Directors’
Deferral Plan (as described below), payable after service on the board has ended.
Lilly Directors’ Deferral Plan
This plan allows directors to defer receipt of all or part of their retainer and meeting fees until after their service
on the board has ended. Each director can choose to invest the funds in either of two accounts:
• Deferred Share Account. This account allows the director, in effect, to invest his or her deferred cash
compensation in Lilly stock. In addition, the annual award of shares to each director noted above (2,840 shares
in 2007) is credited to this account on a pre-set annual date. Funds in this account are credited as hypothetical
shares of Lilly stock based on the market price of the stock at the time the compensation would otherwise have
been earned. Hypothetical dividends are “reinvested” in additional shares based on the market price of the stock
on the date dividends are paid. All shares in the deferred share accounts are hypothetical and are not issued or
transferred until the director ends his or her service on the board.